Shares in GeoVax Labs were up as much as 36% Friday after the company presented data from ongoing studies of its preventive vaccine against COVID-19 at the European Society of Medicine (ESMED) general assembly, as reported in Fidelity.
GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company specializing in developing human vaccines and cancer immunotherapies, today presented data from ongoing studies of its preventive vaccine against COVID-19.